CATHETER RELATED BLOOD STREAM INFECTION MARKET ANALYSIS

Catheter related bloodstream infection arise due to presence of bacteremia at tip of catheter or in between the peripheral intravenous catheter. This Catheter related bloodstream infection are most lethal, frequent, and cost complex expenses because of  high maintenance at hospital for infected patient   and it is called as  nosocomial infection which also known as  health care associated infection caused due to multidrug resistant pathogens acquired during invasive procedure , improper or excessive use of antibiotics and not following proper infection control procedures. It is infected due to intravascular catheter by quantitative culture of the tip of catheter or various microbial growth in between the catheter and peripheral intravenous catheters (PIVs). For instance, according to article published in frontiers journal on August 12, 2021, Candida Species have been reported the most commonly causing source of pathogen for bloodstream infection.

Furthermore, as per the study published in National Center for Biotechnology Information (NCBI) regarding catheter-related bloodstream infection indicates that globally, the number of incidences of catheter related bloodstream infection is estimated to be four million patients.

Global Catheter Related Blood Stream Infection Market – Dynamics

Furthermore, WHO study indicates that most of the countries lack in the surveillance systems for infections related to health care and these reasons often result in struggle with the complexity and lack of standardized criteria for diagnosing the infections. Serious effects are associated with inaccurate diagnosis, results complication or lead to increase in mortality and morbidity. Due to which it is necessary to diagnose catheter related bloodstream infection accurately.

Likewise, the market players are conducting research and development activities for the innovation of better products for the prevention of catheter related blood stream infection. This is expected to increase the growth of the global catheter related bloodstream infection market over the forecast period. For instance, on August 4, 2021, Citius Pharmaceuticals, an  biopharmaceutical company which focused on development and commercialization of products based on critical care. Company announced that, Mino-Lok it is an antibiotic lock solution, which is used for treatment of patients with catheter related bloodstream infection. As per phase 2b trial results Mino lok demonstrated 100 % efficacy rate. And multicenter phase 3 clinical trial of Mino-Lok is currently underway. Mini-Lok by Citius pharmaceuticals has potential to be the first and only Food and Drug Administration (FDA) approved product to be used for infected CVCs and the company plans to file a new drug application (NDA) in 2022.

Due to the rising cases in health care associated infections in the U.S., the government provides reimbursement policy to the patients. For instance, as per programs in centers for Medicare and Medicaid services (CMS), the HAC Reduction Program provide services for catheter related bloodstream infection. This program encourage hospitals to provide safety assurance to infected patients. The Medicare provided through this program is US$ 9,504 Mn.

Global Catheter Related Blood Stream Infection Market – Regional Insights

Among regions, North America extended enormous share of catheter related bloodstream infection in global market during the forecast period, due to the infrastructure establishment in health care. For instance, In the United States , an estimated 250,000 bloodstream infection occur annually, and most are related to the presence of intravascular devices. the rate of bloodstream infection for intensive care units (ICU) is estimated to be 0.8 per 1000 days. The Hospital Acquired Condition (HAC) reduction program by the U.S. government encourages hospitals for patients’ safety. Moreover, as per National Health Expenditures 2019, in the U.S. available on CMS indicates that the upcoming National health spending will increase the annual growth rate by 5.4 % for 2019-2028.

Furthermore, Europe region is expected to anticipate the second largest market after North America from 2020 to 2030. For instance, according to the report published by the European Center for Disease Prevention and Control (ECDC), the prevalence of CVC in Europe is approximately 7.1%. The ECDC center estimates that every year in Europe the number of Catheter related bloodstream infection patients is approximately 4,13, 000 from overall number of patients associated with health care infections.

Global Catheter Related Blood Stream Infection Market – Taxonomy

By Drug Class:

• Non-antibiotic
• Anti-infective
• Antimicrobial 

By Pathogenesis:

• Contaminated Catheter Hub
• Contaminated Infusate
• Skin Insertion
• Hematogenous

By Source of Infection/Micro-organisms:

• Aureus
• aeruginsa
• CONS
• Baumanii
• coli
• pnemoniae
• Candida sp.

By Route of Administration:

• Oral
• Intravenous

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Global Catheter Related Blood Stream Infection Market – Competitive landscape

Key players involved in the global catheter related blood stream infection include Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, AstraZeneca Pharma India Ltd., Glenmark Pharmaceuticals Ltd., Xellia Pharmaceuticals Ltd.,  and Pfizer.